Literature DB >> 12141832

A randomized, double-blind, placebo-controlled trial of interferon-alpha and amantadine versus interferon-alpha alone in the treatment of patients with chronic hepatitis C.

Jawad Ahmad, Hugo Vargas, Vijayan Balan, Jorge Rakela, A Obaid Shakil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12141832     DOI： 10.1023/a:1015804227191

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.487


× No keyword cloud information.
  4 in total

1.  Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

Authors:  S Brillanti; F Levantesi; L Masi; M Foli; L Bolondi
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

2.  In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients.

Authors:  J Martín; S Navas; M Fernández; M Rico; M Pardo; J A Quiroga; F Zahm; V Carreño
Journal:  Antiviral Res       Date:  1999-05       Impact factor: 5.970

3.  Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation.

Authors:  R Jubin; M G Murray; A Y Howe; N Butkiewicz; Z Hong; J Y Lau
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

Review 4.  Antiviral agents.

Authors:  E D Reines; P A Gross
Journal:  Med Clin North Am       Date:  1988-05       Impact factor: 5.456
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.